In January, the Milner Institute announced that Pfizer are the latest partner to join the Milner Therapeutics Consortium, which brings together the drug development capabilities of leading pharmaceutical companies with the ideas and know-how of Cambridge academics.
The other existing industrial partners are Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune and Otsuka and the model for engagement is based upon a pre-signed agreement with each company allowing for speedy exchange of information and resources.
The full press release is available here.